Orchard Therapeutics PLC – (NASDAQ:ORTX) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 2,557,800 shares, an increase of 6.9% from the April 30th total of 2,393,100 shares. Based on an average daily volume of 180,300 shares, the short-interest ratio is presently 14.2 days. Currently, 4.0% of the shares of the company are short sold.
Several hedge funds have recently added to or reduced their stakes in ORTX. Legacy Advisors LLC bought a new position in shares of Orchard Therapeutics during the first quarter valued at $53,000. Lindbrook Capital LLC bought a new position in shares of Orchard Therapeutics during the first quarter valued at $53,000. Exane Derivatives bought a new position in shares of Orchard Therapeutics during the second quarter valued at $60,000. Victory Capital Management Inc. bought a new position in shares of Orchard Therapeutics during the fourth quarter valued at $106,000. Finally, Jabodon PT Co. bought a new position in shares of Orchard Therapeutics during the first quarter valued at $550,000. 57.01% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on ORTX. Wedbush set a $30.00 target price on shares of Aquestive Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 22nd. Zacks Investment Research upgraded shares of York Water from a “sell” rating to a “hold” rating in a research report on Saturday, June 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $23.80.
Orchard Therapeutics (NASDAQ:ORTX) last issued its earnings results on Tuesday, May 28th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.14. On average, equities analysts anticipate that Orchard Therapeutics will post -1.57 EPS for the current year.
About Orchard Therapeutics
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Further Reading: What is an overbought condition?
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.